FINWIRES · TerminalLIVE
FINWIRES

$ARGX

49 stories mentioning ARGXUpdated 5d ago

Every FINWIRES story that references ARGX, newest first.

What are analysts saying about ARGX?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on ARGX?

Asia Markets

European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading

European equities traded in the US as American depositary receipts were tracking lower late Tuesday morning, declining 0.46% to 1,968.02 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm Evaxion (EVAX) and telecommunications company Nokia (NOK), which rose 2.6% and 6.5% respectively. They were followed by petroleum refiner Equinor (EQNR) and oil and gas company Eni (E), which were up 2.3% and 2.2% respectively.The decliners from continental Europe were led by biotech firm BioNTech (BNTX) and internet browser company Opera (OPRA), which fell 4.9% and 2% respectively. They were followed by biopharmaceutical companies argenx (ARGX) and Cellectis (CLLS), which were down 2.2% and 0.3%, respectively.The gainers from the UK were led by biopharmaceutical company Akari Therapeutics (AKTX) and oil and gas company BP (BP), which increased 2% and 2.5% respectively. They were followed by mining company BHP Group (BHP) and oil and gas company Shell (SHEL), which advanced 3.4% and 2.5% respectively.The decliners from the UK and Ireland were led by software firm Endava (DAVA), which lost 6.2%. It was followed by biotech firm Autolus Therapeutics (AUTL) and pharmaceutical company Silence Therapeutics (SLN), which dropped 3.6% and 3.4% respectively.

$AKTX$ARGX$AUTL$BHP$BNTX$BP$CLLS$DAVA$E$EQNR$EVAX$NOK$OPRA$SHEL$SLN
Asia Markets

European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading

European equities traded in the US as American depositary receipts were tracking lower late Wednesday morning, declining 0.46% to 1,977.10 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by accommodations booking site trivago (TRVG) and biopharmaceutical company argenx (ARGX), which advanced 2.9% and 2.6% respectively. They were followed by semiconductor company Sequans Communications (SQNS) and 3D printer company Materialise (MTLS), which rose 2% and 1.2% respectively.The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and software firm SAP (SAP), which fell 3.5% and 2.7% respectively. They were followed by telecommunications company Ericsson (ERIC) and pharmaceutical company Novo Nordisk (NVO), which lost 2.1% and 1.8% respectively.The gainers from the UK were led by biopharmaceutical companies Amarin (AMRN) and Akari Therapeutics (AKTX), which climbed 7.1% and 2.9% respectively. They were followed by tobacco company British American Tobacco (BTI) and biopharmaceutical company Mereo BioPharma Group (MREO), which were up 1.8% and 0.7% respectively.The decliners from the UK and Ireland were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and biotech firm Autolus Therapeutics (AUTL), which dropped 14% and 3.9% respectively. They were followed by software firm Endava (DAVA) and biopharmaceutical company Bicycle Therapeutics (BCYC), which were down 2.2% and 1.8% respectively.

$AKTX$AMRN$ARGX$AUTL$BCYC$BDRX$BTI$DAVA$DBVT$ERIC$MREO$MTLS$NVO$SAP$SQNS$TRVG
Asia Markets

European Equities Traded in the US as American Depositary Receipts Track Slightly Lower in Monday Trading

European equities traded in the US as American depositary receipts started the week slightly lower late Monday morning, declining 0.16% to 1,978.70 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by internet browser company Opera (OPRA) and consumer goods company Unilever (UL), which rose 1.9% and 1.8% respectively. They were followed by lender Banco Santander (SAN) and brewing company Anheuser-Busch InBev (BUD), which were up 1.2% and 1% respectively.The decliners from continental Europe were led by biopharmaceutical company Cellectis (CLLS) and biotech firm BioNTech (BNTX), which dropped 5.1% and 4.2% respectively. They were followed by biopharmaceutical company argenx (ARGX) and telecommunications company Nokia (NOK), which were down 2.8% and 2.6% respectively.The gainers from the UK were led by communications group WPP (WPP) and education company Pearson (PSO), which advanced 3.4% and 2.1% respectively. They were followed by alcoholic beverage company Diageo (DEO) and hospitality company Intercontinental Hotels Group (IHG), which increased 2% each.The decliners from the UK and Ireland were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which fell 5.5%. It was followed by biopharmaceutical company NuCana (NCNA) and biotech firm Autolus Therapeutics (AUTL), which lost 2% and 1% respectively.

$ARGX$AUTL$BDRX$BNTX$BUD$CLLS$DEO$IHG$NCNA$NOK$OPRA$PSO$SAN$UL$WPP
Asia Markets

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

European equities traded in the US as American depositary receipts were tracking higher late Wednesday morning, rising 0.68% to 1,973.64 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech firm BioNTech (BNTX) and biopharmaceutical company Grifols (GRFS), which advanced 24% and 5.6% respectively. They were followed by semiconductor company Sequans Communications (SQNS) and biopharmaceutical company argenx (ARGX), which rose 3.3% and 3% respectively.The decliners from continental Europe were led by internet browser company Opera (OPRA) and biotech firm Evaxion (EVAX), which fell 7.9% and 6% respectively. They were followed by accommodations booking site Trivago (TRVG) and telecommunications company Nokia (NOK), which were down 4.3% and 1.6% respectively.The gainers from the UK were led by biotech firm Autolus Therapeutics (AUTL) and mining company BHP Group (BHP), which increased 9.2% and 4.5% respectively. They were followed by software firm Endava (DAVA) and biopharmaceutical company Bicycle Therapeutics (BCYC), which were up 4% and 3.4% respectively.The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which dropped 3.5% and 1.9% respectively. They were followed by insurance company Prudential (PUK) and medical device maker Smith & Nephew (SNN), which lost 1.3% and 1.1% respectively.

$ARGX$AUTL$BCYC$BDRX$BHP$BNTX$DAVA$EVAX$GRFS$NOK$OPRA$PUK$SNN$SQNS$TRIB$TRVG
Wire

Argenx's Myositis Data Derisk Vyvgart Opportunity, Oppenheimer Says

Argenx's (ARGX) phase 3 data on Vyvgart reduce the uncertainty around its potential $1.5 billion to $2 billion autoimmune myositis opportunity, Oppenheimer said.The phase 3 study of Vyvgart achieved its primary endpoint for the combined dermatomyositis and immune-mediated necrotizing myopathy, or IMNM, population, the investment firm said in a Monday note, noting IMNM as the therapy's "most derisked" path to approval.In the IMNM subgroup, Vyvgart-treated patients showed a 14.8-point greater improvement in mean Total Improvement Score versus placebo at week 52, a statistically significant result with a p-value of 0.0048, Oppenheimer added.The results are a testament to the company's pipeline-in-a-product strategy, bringing it closer to entering rheumatology as a second therapeutic category, according to the noteOppenheimer raised its price target on argenx to $1,100 from $1,037, while keeping its outperform outlook.Shares of Argenx were up 1.1% in Tuesday trading.Price: $998.83, Change: $+10.99, Percent Change: +1.11%

$ARGX
Wire

Argenx's Vyvgart Hytrulo Likely to Get FDA Approval for Myositis, RBC Says

Argenx's (ARGX) Vyvgart Hytrulo is likely to get approval from the US Food and Drug Administration for adults with immune-mediated necrotizing myopathy and dermatomyositis, RBC Capital Markets analysts said in a note emailed Tuesday.Analysts said that even if the FDA decides to play "hard ball" for dermatomyositis approval, a new larger trial is expected to be relatively straightforward.RBC said that for immune-mediated necrotizing myopathy, commercial uptake could be very rapid, given that Vyvgart is the first drug to show benefits in phase 3 and neurologists are already familiar with it.On dermatomyositis, analysts said that while the trial did not reach statistical significance, the Total Improvement Score benefit was consistent with immune-mediated necrotizing myopathy and phase 3 data outperformed phase 2.RBC retained an outperform rating on the stock and increased its price target to $1,100 from $1,025.Price: $995.61, Change: $+7.77, Percent Change: +0.79%

$ARGX
Wire

Argenx's Myositis Data Strengthen Efgartigimod Outlook, Morgan Stanley Says

Argenx's (ARGX) latest myositis data strengthened the outlook for efgartigimod, particularly in immune-mediated necrotizing myopathy, resulting in higher probability-of-success assumptions, Morgan Stanley said in a report Tuesday.Efgartigimod produced a 15.4-point placebo-adjusted improvement in mean Total Improvement Score at week 52 across patients with IMNM and dermatomyositis. The treatment effect was similar in both subtypes, though the DM result did not reach statistical significance.Morgan Stanley raised the probability of success for efgartigimod in IMNM to 90% and in DM to 65%. IMNM is viewed as the "near-term" and "higher-probability" opportunity, with the company's management planning to pursue a filing "with urgency" under Breakthrough Therapy Designation and seek priority review, according to the report.The investment firm estimates myositis could contribute about $3.4 billion in worldwide risk-adjusted revenue by 2036, including about $1.8 billion from IMNM and $1.5 billion from DM.Morgan Stanley has an overweight rating on Argenx and raised its price target to $1,230 from $1,200, saying the IMNM opportunity is "strong enough to stand on its own" while DM represents additional upside.Price: $995.09, Change: $+7.25, Percent Change: +0.73%

$ARGX
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index down 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.2%.The iShares Biotechnology ETF (IBB) added 1.8%.In corporate news, OmniAb (OABI) unveiled a partnership with Eli Lilly (LLY) on a new ion-channel drug discovery program, while raising its fiscal 2026 cash and cash equivalents guidance. OmniAb shares jumped nearly 13%, and Lilly was up 0.4%.Freenome (FRNM) shares surged past 12% after Jefferies initiated coverage of the stock with a buy rating and a price target of $17.Argenx (ARGX) shares climbed 16% after the company said a phase 3 study evaluating its experimental drug Vyvgart Hytrulo in adults with autoimmune myositis met its main goal.EyePoint (EYPT) shares tumbled 67% after it said its phase 3 Lugano trial testing Duravyu in people with wet age-related macular degeneration failed to achieve its primary endpoint.

$ARGX$EYPT$FRNM$LLY$OABI
Wire

Update: argenx Shares Rise After Autoimmune Myositis Drug Meets Main Goal in Phase 3 Study

(Updates with reporting date in the first paragraph, and the latest stock move in the headline and first paragraph)argenx (ARGX) shares rose more than 16% in Monday trading after the company said a phase 3 study evaluating its experimental drug, Vyvgart Hytrulo, in adults with autoimmune myositis met its main goal.The company said the patients treated with the drug showed a statistically significant improvement in mean total improvement score at week 52 compared with placebo.Treatment benefits emerged as early as week 4 and were sustained through the 52-week treatment period, including during steroid tapering, the company said.argenx said the primary endpoint was also met in patients with immune-mediated necrotizing myopathy, while dermatomyositis patients showed a similar improvement, although it did not reach statistical significance.Price: $989.87, Change: $+138.58, Percent Change: +16.28%

$ARGX
Sectors

Sector Update: Healthcare Stocks Mixed Monday Afternoon

Healthcare stocks were mixed Monday afternoon, with the NYSE Healthcare Index up nearly 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) fractionally lower.The iShares Biotechnology ETF (IBB) climbed up 1.8%.In corporate news, UroGen Pharma (URGN) shares rose 2.1% after the firm said it has submitted a new drug application to the US Food and Drug Administration for UGN-103 to treat adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.Argenx (ARGX) shares surged past 16% after the company said a phase 3 study evaluating its experimental drug Vyvgart Hytrulo in adults with autoimmune myositis met its main goal.Mesoblast (MESO) shares jumped nearly 10% after the company said it has completed patient treatment in a phase 3 trial of its experimental rexlemestrocel-L for chronic low back pain associated with degenerative disc disease.EyePoint (EYPT) shares tumbled 68% after it said its phase 3 Lugano trial testing Duravyu in people with wet age-related macular degeneration failed to achieve its primary endpoint.

$ARGX$EYPT$MESO$URGN
Asia Markets

European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading

European equities traded in the US as American depositary receipts started the week tracking modestly higher late Monday morning, rising 0.31% to 1,970.56 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical companies argenx (ARGX) and DBV Technologies (DBVT), which climbed 16% and 5.1% respectively. They were followed by telecommunications company Nokia (NOK) and biopharmaceutical company Cellectis (CLLS), which advanced 2.5% and 2% respectively.The decliners from continental Europe were led by medical device maker EDAP TMS (FOCL) and internet browser company Opera (OPRA), which dropped 4.6% and 2.7% respectively. They were followed by brewing company Anheuser-Busch InBev (BUD) and consumer goods company Unilever (UL), which lost 2.4% and 1.6% respectively.The gainers from the UK were led by biotech firm Autolus Therapeutics (AUTL) and biopharmaceutical company Akari Therapeutics (AKTX), which rose 6.3% and 2.8% respectively. They were followed by biopharmaceutical companies GSK (GSK) and Bicycle Therapeutics (BCYC), which were up 1.6% and 1.5% respectively.The decliners from the UK and Ireland were led by biopharmaceutical company Mereo BioPharma Group (MREO) and communications company WPP (WPP), which fell 5.4% and 3% respectively. They were followed by alcoholic beverage company Diageo (DEO) and biopharmaceutical company NuCana (NCNA), which decreased 2.6% and 2.5% respectively.

$AKTX$ARGX$AUTL$BCYC$BUD$CLLS$DBVT$DEO$FOCL$GSK$MREO$NCNA$NOK$OPRA$UL$WPP
Wire

Wedbush Adjusts Argenx PT to $1,150 From $1,050, Maintains Outperform Rating

Argenx (ARGX) has an average rating of buy and mean price target of $1,094.70, according to analysts polled by FactSet.Price: $981.93, Change: $+130.64, Percent Change: +15.35%

$ARGX
Sectors

Sector Update: Healthcare Stocks Mixed Premarket Monday

Healthcare stocks were mixed premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.5% lower and the iShares Biotechnology ETF (IBB) up 0.2%.Argenx (ARGX) shares were up more than 11% after the company said a phase 3 study evaluating its experimental drug, Vyvgart Hytrulo, in adults with autoimmune myositis met its main goal.EyePoint (EYPT) stock was down past 69% after the company said its phase 3 Lugano trial testing Duravyu in patients with wet age-related macular degeneration failed to achieve its primary endpoint.Mesoblast (MESO) shares were up nearly 10% after the company said it has completed patient treatment in a phase 3 trial of its experimental rexlemestrocel-L for chronic low back pain associated with degenerative disc disease.

$ARGX$EYPT$IBB$MESO$XLV
Commodities

Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Monday Amid Lower Rate Hike Expectations

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively traded Invesco QQQ Trust (QQQ) was 0.5% higher in Monday's premarket activity amid lower expectations of an interest rate increase.US stock futures were mixed, with S&P 500 Index futures up 0.1%, Dow Jones Industrial Average futures slipping 0.1%, and Nasdaq futures gaining 0.5% before the start of regular trading.The New York Federal Reserve's Empire State manufacturing index rose to 20.6 in August from 15.6 in July, compared with an expected decrease to a reading of 10.0 in a survey compiled by Bloomberg.The National Association of Home Builders' housing market index for August will be released at 10 am ET.In premarket action, bitcoin was up by 0.8%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.8% higher, Ether ETF (EETH) advanced 1.4%, and Bitcoin & Ether Market Cap Weight ETF (BETH) was flat.Power Play:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) retreated 0.4%, the Vanguard Health Care Index Fund (VHT) was down 0.1%, while the iShares US Healthcare ETF (IYH) slipped 0.1%. The iShares Biotechnology ETF (IBB) was up 0.4%.Argenx (ARGX) stock was up more than 11% premarket after the company said a phase 3 study evaluating its experimental drug, Vyvgart Hytrulo, in adults with autoimmune myositis met its primary endpoint.Winners and Losers:EnergyThe iShares US Energy ETF (IYE) was down 0.1%, while the State Street Energy Select Sector SPDR ETF (XLE) retreated 0.1%.Vista Energy (VIST) stock was up more than 4% before market open after a 3.2% rise at Friday's close. A US Securities and Exchange Commission filing published Friday showed that Palantir Technologies (PLTR) Co-Founder Peter Thiel has acquired 1,189,792 American depositary shares in the Argentinian energy company worth about $75.9 million. Palantir stock was 0.6% lower.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.02%, the Vanguard Industrials Index Fund (VIS) was up 0.1%, and the iShares US Industrials ETF (IYJ) was inactive.L3Harris Technologies (LHX) stock was down more than 2% before the opening bell after the company said it appointed Sam Mehta as President and CEO to succeed Christopher Kubasik, who stepped down as chairman and CEO following an investigation.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.6%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) retreated by 0.5%, and the iShares US Consumer Staples ETF (IYK) was 1% lower. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) gained 0.2%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was 0.1% higher.Amazon (AMZN) shares were up more than 1% pre-bell. According to updated user conditions posted on the company's website Friday, Amazon has reinstated binding arbitration for its US customers and barred them from pursuing class action lawsuits.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) retreated 0.3%. Direxion Daily Financial Bull 3X Shares (FAS) was down 0.9%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 1% higher.Riot Platform (RIOT) shares traded up 1% in early hours activity after the company said its wholly owned subsidiary, Riot DC Logistics, entered into a $573 million senior secured delayed-draw term loan credit agreement on Aug. 10.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) gained 0.3%, the iShares US Technology ETF (IYW) was 0.6% higher, and the iShares Expanded Tech Sector ETF (IGM) was up 0.3%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) advanced 1,4%, while the iShares Semiconductor ETF (SOXX) rose by 1%.Nvidia (NVDA) shares were up 0.7% after a Friday filing with the US Securities and Exchange Commission showed that the company has a $29.99 billion stake in Intel (INTC) and a $20.98 billion stake in Space Exploration Technologies (SPCX) as of June 30. Intel stock was 0.6% higher, while SpaceX was marginally lower.CommoditiesFront-month US West Texas Intermediate crude oil gained by 0.4% to reach $82.73 per barrel on the New York Mercantile Exchange. Natural gas was down 2.1% at $2.68 per 1 million British Thermal Units. The United States Oil Fund (USO) gained 0.9%, while the United States Natural Gas Fund (UNG) was 1.7% lower.Gold futures for November were up by 0.2% at $4,443.90 an ounce on the Comex. Silver futures advanced 0.9% to $65.66 an ounce. SPDR Gold Shares (GLD) gained by 0.1%, and the iShares Silver Trust (SLV) was 0.8% higher.

Dow JonesNasdaq CompositeS&P 500$AMZN$ARGX$BETH$BITO$EEM$EETH$EXI$FAS$FAZ$GLD$IBB$IGM$IGV$INTC$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$LHX$NVDA$PLTR$PMR$QQQ$RIOT$RTH$SLV$SOXX$SPCX$SPY$UNG$USO$VDC$VHT$VIS$VIST$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Sectors

Sector Update: Healthcare

Healthcare stocks were mixed premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.5% lower and the iShares Biotechnology ETF (IBB) up 0.2%.Argenx (ARGX) shares were nearly 12% higher after the company said a phase 3 study evaluating its experimental drug, Vyvgart Hytrulo, in adults with autoimmune myositis met its main goal.

$ARGX
Wire

Update: argenx Says Autoimmune Myositis Drug Meets Main Goal in Phase 3 Study

(Updates with reporting date in the first paragraph and the latest stock move in the last paragraph)argenx (ARGX) said Monday a phase 3 study evaluating its experimental drug, Vyvgart Hytrulo, in adults with autoimmune myositis met its main goal.The company said the patients treated with the drug showed a statistically significant improvement in mean total improvement score at week 52 compared with placebo.Treatment benefits emerged as early as week 4 and were sustained through the 52-week treatment period, including during steroid tapering, the company said.argenx said the primary endpoint was also met in patients with immune-mediated necrotizing myopathy, while dermatomyositis patients showed a similar improvement, although it did not reach statistical significance.Shares of Argenx were up over 7% in recent premarket trading.Price: $918.18, Change: $+66.89, Percent Change: +7.86%

$ARGX
Asia Markets

European Equities Traded in the US as American Depositary Receipts Track Lower in Friday Trading

European equities traded in the US as American depositary receipts were tracking lower late Friday morning, declining 0.35% to 1,962.14 on the S&P Europe Select ADR Index, which is up 0.17% for the week so far.From continental Europe, the gainers were led by semiconductor company Sequans Communications (SQNS) and petroleum refiner Equinor (EQNR), which rose 3.2% and 2.3%, respectively. They were followed by oil and gas company Eni (E) and telecommunications firm Nokia (NOK), which were up 0.8% and 0.7%, respectively.The decliners from continental Europe were led by biopharmaceutical companies Cellectis (CLLS) and argenx (ARGX), which dropped 2.5% and 2.1%, respectively. They were followed by biopharmaceutical firm DBV Technologies (DBVT) and biotech company Evaxion (EVAX), which lost 1.8% and 1.6%, respectively.The gainers from the UK were led by biopharmaceutical company NuCana (NCNA) and biotech firm Trinity Biotech (TRIB), which advanced 4.1% and 3.1% respectively. They were followed by oil and gas companies Shell (SHEL) and BP (BP), which increased 1.7% and 0.9% respectively.The decliners from the UK and Ireland were led by biotech firm Autolus Therapeutics (AUTL) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which fell 7.4% and 3.9% respectively. They were followed by biopharmaceutical companies Bicycle Therapeutics (BCYC) and Akari Therapeutics (AKTX), which were down 2.3% and 1.3% respectively.

$AKTX$ARGX$AUTL$BCYC$BDRX$BP$CLLS$DBVT$E$EQNR$EVAX$NCNA$NOK$SHEL$SQNS$TRIB
Asia Markets

European Equities Traded in the US as American Depositary Receipts Edge Up in Wednesday Trading

European equities traded in the US as American depositary receipts were edging higher late Wednesday morning, up 0.2% to 1,940.47 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company DBV Technologies (DBVT) and semiconductor firm Sequans Communications (SQNS), which rose 3.6% and 3.3% respectively. They were followed by argenx (ARGX) and Novo Nordisk (NVO), which rose 3.2% and 2.8% respectively.The decliners from continental Europe were led by internet ad firm Criteo (CRTO) and biopharmaceutical company Cellectis (CLLS), which dropped 18% and 1.8% respectively. They were followed by telecommunications company Nokia (NOK) and biopharmaceutical company Grifols (GRFS), which were down 1.5% and 1.3% respectively.The gainers from the UK were led by pharmaceutical company AstraZeneca (AZN) and communications company WPP (WPP), which increased 4.6% and 3.4% respectively. They were followed by educational publisher Pearson (PSO) and hospitality company Intercontinental Hotels Group (IHG), which were up 2.5% and 2.1% respectively.The decliners from the UK and Ireland were led by Biodexa Pharmaceuticals (BDRX) and insurance company Prudential (PUK), which fell 8.1% and 4.7% respectively. They were followed by Akari Therapeutics (AKTX) and lender HSBC (HSBC), which lost 3.6% and 3.2% respectively.

$AKTX$ARGX$AZN$BDRX$CLLS$CRTO$DBVT$GRFS$HSBC$IHG$NOK$NVO$PSO$PUK$SQNS$WPP
Asia Markets

European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading

European equities traded in the US as American depositary receipts started the week off lower late Monday morning, declining 0.35% to 1,925.58 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by accommodations booking site trivago (TRVG) and software firm SAP (SAP), which rose 4% and 3.3%, respectively. They were followed by telecommunications company Ericsson (ERIC) and 3D printer company Materialise (MTLS), which were up 2.5% and 2.4%, respectively.The decliners from continental Europe were led by petroleum refiner Equinor (EQNR) and brewing company Anheuser-Busch InBev (BUD), which dropped 2.8% and 2.4%, respectively. They were followed by oil and gas company Eni (E) and biopharmaceutical company argenx (ARGX), which were down 2.2% and 1.9%, respectively.The gainers from the UK were led by biotech firm Autolus Therapeutics (AUTL) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which advanced 30% and 6.8%, respectively. They were followed by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company NuCana (NCNA), which increased 5.9% and 3%, respectively.The decliners from the UK and Ireland were led by pharmaceutical company AstraZeneca (AZN) and biotech firm Trinity Biotech (TRIB), which fell 8.1% and 2.9%, respectively. They were followed by oil and gas company BP (BP) and biopharmaceutical company Akari Therapeutics (AKTX), which lost 2.3% and 2.1%, respectively.

$AKTX$ARGX$AUTL$AZN$BDRX$BP$BUD$E$EQNR$ERIC$MTLS$NCNA$SAP$SLN$TRIB$TRVG
Asia Markets

European Equities Traded in the US as American Depositary Receipts Track Sharply Higher in Thursday Trading

European equities traded in the US as American depositary receipts were tracking sharply higher late Thursday morning, rising 1.84% to 1,938.04 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by telecommunications company Nokia (NOK) and lender ING Group (ING), which advanced 9.8% and 7% respectively. They were followed by lenders Banco Bilbao Vizcaya Argentaria (BBVA) and Banco Santander (SAN), which climbed 6.8% and 4.6% respectively.The decliners from continental Europe were led by pharmaceutical company Sanofi (SNY) and software firm SAP (SAP), which lost 6.2% and 2.8% respectively. They were followed by internet ad firm Criteo (CRTO) and biopharmaceutical company argenx (ARGX), which dropped 2.5% and 1.8% respectively.The gainers from the UK were led by lenders Barclays (BCS) and Lloyds Banking Group (LYG), which rose 5.6% and 5.4% respectively. They were followed by insurance firm Prudential (PUK) and biopharmaceutical company Mereo BioPharma Group (MREO), which were up 4.8% and 1.6% respectively.The decliners from the UK and Ireland were led by software firm Endava (DAVA) and communications company WPP (WPP), which fell 6.4% and 5.8% respectively. They were followed by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Akari Therapeutics (AKTX), which were down 4.4% and 2.9% respectively.

$AKTX$ARGX$BBVA$BCS$CRTO$DAVA$ING$LYG$MREO$NOK$PUK$SAN$SAP$SNY$TRIB$WPP

Showing 1-20 of 49

Track with the FINWIRES app suite

FolioX
FolioX
Track ARGX in your portfolio
WheelAI
WheelAI
Analyze ARGX options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ARGX